Ignite Creation Date:
2024-05-05 @ 12:07 PM
Last Modification Date:
2024-10-26 @ 9:20 AM
Study NCT ID:
NCT00242814
Status:
COMPLETED
Last Update Posted:
2023-12-08
First Post:
2005-10-19
Brief Title:
Phase IV 9 Weeks Comparison Between MICARDIS 80 mg and Amlodipine 10 mg on Biological PPAR Gamma Activities
Sponsor:
Boehringer Ingelheim
Organization:
Boehringer Ingelheim
Study Overview
Official Title:
A Phase IV Study Prospective Randomised Open Label Blinded Endpoint Parallel Group 9 Weeks of Comparison Between Oral Administration of Telmisartan Tablet 80mg Once Daily and Amlodipine Tablet 10 mg Once Daily on Biological PPAR Gamma Activities in Non Controlled Hypertensive Male Patients With Metabolic Syndrome
Status:
COMPLETED
Status Verified Date:
2023-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The objective of the study is to compare PPAR activities increase of adiponectin level between MICARDIS and amlodipine after 6 weeks of treatment in hypertensive patients with metabolic syndrome Moreover this study will compare serum level of inflammatory markers of the metabolic syndrome after 6 weeks of treatment
An ancillary study performed in one center will assess adipocyte differentiation PPAR gamma stimulation in 30 subjects 15 per arm
An ancillary study performed in one center will assess adipocyte differentiation PPAR gamma stimulation in 30 subjects 15 per arm
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None